Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:drug |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01EB07
|
| gptkbp:brand |
gptkb:Vizimpro
|
| gptkbp:CASNumber |
1110813-31-4
|
| gptkbp:developedBy |
gptkb:Pfizer
|
| gptkbp:hasMolecularFormula |
C24H25ClFN5O2
|
| gptkbp:hasSMILES |
COc1cc(NC(=O)C2CCN(CC2)C(=O)c3c(C)cc(Nc4nccc(F)n4)cc3Cl)ccc1C
|
| https://www.w3.org/2000/01/rdf-schema#label |
dacomitinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
irreversible EGFR inhibitor
|
| gptkbp:molecularWeight |
469.94 g/mol
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
weight loss alopecia rash dry skin decreased appetite stomatitis paronychia |
| gptkbp:target |
gptkb:EGFR
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:bfsParent |
gptkb:P15056
gptkb:P42338 |
| gptkbp:bfsLayer |
6
|